Status:
COMPLETED
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
Lead Sponsor:
National Taiwan University Hospital
Conditions:
NSCLC
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2 or or unresectable stage IIIb 2.KPS\>70% 3.Hb\>10g/dl,ANC\>2.0x109/L,Plt.\>100x109/L4.T-bil.\<1xULN,creatinine\<1xULN,creatinine clearance \>60 ml/min,GPT/GOT\<2.5xULN,ALP\<5xULN
Exclusion
- Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00172380
Start Date
February 1 2005
End Date
March 1 2010
Last Update
December 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, National Taiwan University Hospital
Taipei, Taiwan, 100